Literature DB >> 1524078

Clinical comparison of cefuroxime axetil and amoxicillin/clavulanate in the treatment of patients with acute bacterial maxillary sinusitis.

A E Camacho1, R Cobo, J Otte, S L Spector, C J Lerner, N A Garrison, A Miniti, P K Mydlow, G C Giguere, J J Collins.   

Abstract

PURPOSE: This multicenter study compared the clinical and bacteriologic efficacy of two oral antibiotics, cefuroxime axetil and amoxicillin/clavulanate, in the treatment of acute bacterial maxillary sinusitis. PATIENTS AND METHODS: Three hundred seventeen patients with clinical and radiographic evidence of acute maxillary sinusitis were enrolled at nine centers and were randomly assigned to receive 10 days of treatment with cefuroxime axetil 250 mg twice daily (n = 157) or amoxicillin/clavulanate 500 mg three times daily (n = 160). Patients were assessed for both clinical and bacteriologic responses once during treatment (5 to 7 days) and twice after treatment (1 to 3 days and 4 weeks). Bacteriologic assessments were based on needle aspirates of the maxillary sinus obtained pretreatment and, when possible, at the first posttreatment visit.
RESULTS: Organisms were isolated from the pretreatment sinus aspirates of 198 of 317 (62%) patients, with the primary isolates being Streptococcus pneumoniae (22%), Haemophilus spp. (17%), Staphylococcus aureus (13%), and Haemophilus influenzae (10%). A satisfactory clinical outcome (cure or improvement) was achieved in 85% (98 of 115) and 82% (102 of 124) of the clinically evaluable patients treated with cefuroxime axetil or amoxicillin/clavulanate, respectively (P = 0.446). With respect to the eradication of the bacterial pathogens, a satisfactory outcome (cure or presumed cure) was obtained in 84% (31 of 37) and 87% (34 of 39) of bacteriologically evaluable patients treated with cefuroxime axetil or amoxicillin/clavulanate, respectively (p = 0.567). Treatment with amoxicillin/clavulanate was associated with a significantly higher incidence of drug-related adverse events (13% versus 3%, p = 0.001), particularly diarrhea (8% versus 1%, p = 0.001). Two patients in the cefuroxime axetil group and three patients in the amoxicillin/clavulanate group withdrew from the study due to adverse events.
CONCLUSIONS: Our results indicate that cefuroxime axetil twice a day is as effective as amoxicillin/clavulanate three times a day in the treatment of acute bacterial maxillary sinusitis but produces fewer adverse effects.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1524078     DOI: 10.1016/0002-9343(92)90232-z

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  10 in total

1.  Economic evaluation of antibacterials in the treatment of acute sinusitis.

Authors:  C Laurier; J Lachaine; M Ducharme
Journal:  Pharmacoeconomics       Date:  1999-01       Impact factor: 4.981

Review 2.  Rhinosinusitis diagnosis and management for the clinician: a synopsis of recent consensus guidelines.

Authors:  Eli O Meltzer; Daniel L Hamilos
Journal:  Mayo Clin Proc       Date:  2011-04-13       Impact factor: 7.616

Review 3.  Cefuroxime axetil: an updated review of its use in the management of bacterial infections.

Authors:  L J Scott; D Ormrod; K L Goa
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 4.  Diagnosis and management of sinusitis.

Authors:  K L Evans
Journal:  BMJ       Date:  1994-11-26

Review 5.  Diagnosis and treatment of acute and subacute sinusitis in children and adults.

Authors:  G A Incaudo; L G Wooding
Journal:  Clin Rev Allergy Immunol       Date:  1998 Spring-Summer       Impact factor: 10.817

6.  Effectiveness of short-course therapy (5 days) with cefuroxime axetil in treatment of secondary bacterial infections of acute bronchitis.

Authors:  D Henry; G E Ruoff; J Rhudy; A Puopolo; M Drehobl; J Schoenberger; G Giguere; J J Collins
Journal:  Antimicrob Agents Chemother       Date:  1995-11       Impact factor: 5.191

7.  Cefuroxime-induced lupus.

Authors:  Ebru Uz; Nuket Bavbek; Faruk Hilmi Turgut; Mehmet Kanbay; Arif Kaya; Ali Akcay
Journal:  J Natl Med Assoc       Date:  2007-09       Impact factor: 1.798

8.  Cefprozil versus Cefuroxime Axetil in the Treatment of Acute Sinusitis.

Authors:  E R Brankston; H S Conter; R Corriveau; J M Martel; C Laroche; R Roy; C Savard; D Roy; R Kelly; P Forget; M Rivard; F Boulerice
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

Review 9.  Sinusitis. A review for generalists.

Authors:  J B Reuler; L M Lucas; K L Kumar
Journal:  West J Med       Date:  1995-07

Review 10.  Cefuroxime axetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  C M Perry; R N Brogden
Journal:  Drugs       Date:  1996-07       Impact factor: 9.546

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.